October 20, 2015
1 min read

FDA approves Coagadex for hereditary Factor X deficiency

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA today approved Coagadex for hereditary Factor X deficiency.

Coagadex (Bio Products Laboratory) — a high-purity human Factor X concentrate — is the first specific coagulation factor replacement therapy available for patients with this condition.

The Factor X protein activates enzymes to help ensure normal clotting in the body. Factor X deficiency, an inherited disorder, prevents the blood from clotting as it should.

Individuals with the condition typically are treated with fresh-frozen plasma or plasma-derived prothrombin complex concentrates to stop or prevent bleeding.

“The approval of Coagadex is a significant advancement for patients who suffer from this rare but serious disease,” Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research, said in a press release.

Coagadex, derived from human plasma, is indicated for patients aged 12 years or older with hereditary Factor X deficiency who require on-demand treatment and control of bleeding episodes. It also is indicated for perioperative management of bleeding among patients with mild hereditary Factor X deficiency.

The FDA based the approval in part on results of a multicenter study that assessed Coagadex for the treatment of spontaneous, traumatic and heavy menstrual bleeding episodes.

The study included 16 participants who experienced a combined 208 bleeding episodes. Results showed Coagadex effectively controlled bleeding episodes in participants with moderate to severe hereditary Factor X deficiency.

In a separate analysis, perioperative management with Coagadex effectively controlled blood loss during and after surgery in patients with mild Factor X deficiency.

Researchers did not identify any safety concerns in either study.